122 related articles for article (PubMed ID: 18945509)
21. Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis.
Huang HK; Yeh JI
Diabetes Res Clin Pract; 2019 Jun; 152():103-110. PubMed ID: 31108137
[TBL] [Abstract][Full Text] [Related]
22. A comment on 'the risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy'.
Chang Y; Choi NK; Hahn S; Park BJ
Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1072-3; author reply 1073-4. PubMed ID: 17907252
[No Abstract] [Full Text] [Related]
23. Effects of coronary artery disease and percutaneous intervention on the cardiac metabolism of nonesterified fatty acids and insulin: Implications of diabetes mellitus.
Jaumdally RJ; Lip GY; Patel JV; MacFadyen RJ; Varma C
J Intern Med; 2009 Jun; 265(6):689-97. PubMed ID: 19226374
[TBL] [Abstract][Full Text] [Related]
24. Mortality risk with sulphonylureas compared to metformin.
Holden SE; Currie CJ
Diabetes Obes Metab; 2014 Oct; 16(10):885-90. PubMed ID: 24533964
[TBL] [Abstract][Full Text] [Related]
25. Possible risk of sulphonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease.
Fasching P
Diabetologia; 1998 Jun; 41(6):743-4. PubMed ID: 9662063
[No Abstract] [Full Text] [Related]
26. Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea.
Becker ML; Aarnoudse AJ; Newton-Cheh C; Hofman A; Witteman JC; Uitterlinden AG; Visser LE; Stricker BH
Pharmacogenet Genomics; 2008 Jul; 18(7):591-7. PubMed ID: 18551039
[TBL] [Abstract][Full Text] [Related]
27. Risk factors associated with symptomatic hypoglycemia in type 2 diabetes mellitus patients.
Durán-Nah JJ; Rodríguez-Morales A; Smitheram J; Correa-Medina C
Rev Invest Clin; 2008; 60(6):451-8. PubMed ID: 19378831
[TBL] [Abstract][Full Text] [Related]
28. [Increased cardiovascular risk in patients with type 2 diabetes treated with sulfonylurea?].
Asvold BO; Jonsbu M; Grill V
Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2560-4. PubMed ID: 11070997
[TBL] [Abstract][Full Text] [Related]
29. Sulphonylureas in the management of type 2 diabetes during the fasting month of Ramadan.
Zargar A; Basit A; Mahtab H
J Indian Med Assoc; 2005 Aug; 103(8):444-6. PubMed ID: 16363203
[TBL] [Abstract][Full Text] [Related]
30. Coronary artery disease alters ventricular repolarization dynamics in type 2 diabetes.
Vrtovec B; Sinkovec M; Starc V; Radovancevic B; Schlegel TT
Pacing Clin Electrophysiol; 2005 Jan; 28 Suppl 1():S178-81. PubMed ID: 15683491
[TBL] [Abstract][Full Text] [Related]
31. Exenatide and acute pancreatitis.
Tripathy NR; Basha S; Jain R; Shetty S; Ramachandran A
J Assoc Physicians India; 2008 Dec; 56():987-8. PubMed ID: 19322980
[TBL] [Abstract][Full Text] [Related]
32. Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice.
Lee YH; Lee CJ; Lee HS; Choe EY; Lee BW; Ahn CW; Cha BS; Lee HC; Balkau B; Kang ES
Diabetes Metab; 2015 Jun; 41(3):208-15. PubMed ID: 25687901
[TBL] [Abstract][Full Text] [Related]
33. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
Balasubramanian R; Varadharajan S; Kathale A; Nagraj LM; Periyandavar I; Nayak UP; Sharma A; Bolmall C; Baliga VP
J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
[TBL] [Abstract][Full Text] [Related]
34. The role of sulphonylureas in the management of type 2 diabetes mellitus.
Rendell M
Drugs; 2004; 64(12):1339-58. PubMed ID: 15200348
[TBL] [Abstract][Full Text] [Related]
35. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
Hemmingsen B; Lund SS; Vaag A
Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
[TBL] [Abstract][Full Text] [Related]
36. Association of APOE polymorphisms with diabetes and cardiometabolic risk factors and the role of APOE genotypes in response to anti-diabetic therapy: results from the AIDHS/SDS on a South Asian population.
Sapkota B; Subramanian A; Priamvada G; Finely H; Blackett PR; Aston CE; Sanghera DK
J Diabetes Complications; 2015; 29(8):1191-7. PubMed ID: 26318958
[TBL] [Abstract][Full Text] [Related]
37. 'Warm-up' phenomenon in diabetic patients with stable angina treated with diet or sulfonylureas.
Bilinska M; Potocka J; Korzeniowska-Kubacka I; Piotrowicz R
Coron Artery Dis; 2007 Sep; 18(6):455-62. PubMed ID: 17700217
[TBL] [Abstract][Full Text] [Related]
38. [Sulphonylurea derivatives and the cardiovascular system].
Filipiak KJ
Przegl Lek; 2000; 57 Suppl 4():19-22. PubMed ID: 11293225
[TBL] [Abstract][Full Text] [Related]
39. Glipizide and glyburide.
Kure J
N C Med J; 1986 Mar; 47(3):149-53. PubMed ID: 3083269
[No Abstract] [Full Text] [Related]
40. Balancing risk and benefit with oral hypoglycemic drugs.
Hamnvik OP; McMahon GT
Mt Sinai J Med; 2009 Jun; 76(3):234-43. PubMed ID: 19421967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
